Last reviewed · How we verify
Pioglitazone and atorvastatin
At a glance
| Generic name | Pioglitazone and atorvastatin |
|---|---|
| Also known as | ACTOS®, AD4833 |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease (PHASE4)
- The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT) (PHASE4)
- Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome (PHASE1, PHASE2)
- ARREST PAD (Peripheral Arterial Disease) (PHASE2, PHASE3)
- Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines (NA)
- Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba (PHASE4)
- Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pioglitazone and atorvastatin CI brief — competitive landscape report
- Pioglitazone and atorvastatin updates RSS · CI watch RSS
- Takeda portfolio CI